Comparison of Biomedical Variables in PCOS Patients with Normal Iranian Women
-
Maryam Bagheri
,
Farnaz Sohrabvand
,
Mahnaz Lankarani
,
Zahra Zandieh
,
Fedyeh Haghollahi
,
Mamak Shariat
Abstract
Objective:To compared serum CRP levels and biochemical relation in PCOS patients with normal Iranian women.
Materials and methods:This case-control study was performed on 52 individuals with PCOS (Rotterdam 2003 criteria). The cases were compared to 104 healthy non-PCOS, 20 to 35-year-old female subjects with no history of diabetes or renal diseases. Blood samples were taken on the 2(nd) to the 5(th) day of menstrual cycle for the evaluation of CRP levels, triglyceride, insulin, androstronedion, testestrone and total cholesterol.
Results:The mean CRP was 1.38 (± 0.43) mg /dl in the PCOS group, and 1.08 (± 0.49) mg /dl (p= 0.240) in control group.High-Sensitivity C-Reactive Protein (HS-CRP) was positively correlated with the Body Mass Index (BMI) (r = 0.36, p= 0. 001). Before adjusting for age and BMI, CRP was correlated with LDL (r= 0.16, p= 0.03), total cholesterol (TC) (r= 0.17, p= 0. 03), Triglycerid (TG) (r= 0.23, p= 0.003), and the insulin (r= 0.20, p= 0. 01) notably in PCOS group. However, after adjustment was made for age and BMI, the correlation was attenuated in PCOS. The regression analyses depicted that CRP level was not under the influence of other medical parameters Conclusion:
Conclusion:The results showed that mean CRP level was not significantly different between PCOs and normal women. After adjustment for age and BMI, CRP was not associated with any biochemical marker evaluated in this study. It seems that studied biochemical serum levels were mostly associated with obesity. So reduction of BMI may normalize the serum levels of CRP and other biochemical parameters.
Carmina E, Rosato F, Janno A, Rizzo M, Longo RA. Extensive clinical experience: relative prevalence of different androgen excess disorders in 950 women referred because of clinical hyperandrogenism. J Clin Endocrinol Metab 2006;91:2-6.
Dunaif A, Thomas A. Current concepts in the polycystic ovary syndrome. Annu Rev Med 2001;52:401-19.
EhrmannDA. Polycystic ovary syndrome.NEngl JMed 2005;352:1223-36.
Laven JS, Imani B, Eijkemans MJ, Fauser BC. New approach to polycystic ovary syndrome and other forms of anovulatory infertility. Obstet Gynecol Surv 2002;57:755-67.
Talbott EO, Zborowski JV, Sutton-Tyrrell K, McHugh- Pemu KP, Guzick DS Cardiovascular risk in women with polycystic ovary syndrome. Obstet Gynecol Clin North Am.2001; 28:111-133.
Robinson S, Henderson AD, Gelding SV, Kiddy D, Niththyananthan R, Bush A, et al. Dyslipidaemia is associated with insulin resistance in women with polycystic ovaries. Clin Endocrinol (Oxf) 1996;44:277- 84.
Talbott E, Clerici A, Berga SL, Kuller L, Guzick D, Detre K, et al. Adverse lipid and coronary heart disease risk profiles in young women with polycystic ovary syndrome: results of a case-control study. J Clin Epidemiol 1998;51:415-22.
Legro RS, Kunselman AR, Dunaif A. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. Am J Med 2001;111:607-13.
Pirwany IR, Fleming R, Greer IA, Packard CJ, Sattar N. Lipids and lipoprotein subfractions in women with PCOS: relationship to metabolic and endocrine parameters. Clin Endocrinol (Oxf) 2001;54:447-53.
Talbott EO, Guzick DS, Sutton-Tyrrell K, McHugh- Pemu KP, Zborowski JV, Remsberg KE, et al.
Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women. Arterioscler Thromb Vasc Biol 2000;20:2414-21.
Paradisi G, Steinberg HO, Hempfling A, Cronin J, Hook G, Shepard MK, et al. Polycystic ovary syndrome is associated with endothelial dysfunction. Circulation 2001;103:1410-5.
Christian RC, Dumesic DA, Behrenbeck T, Oberg AL, sheedy PF 2nd, Fitzpatrick LA. Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003;88:2562-8.
Park R, Detrano R, Xiang M, Fu P, Ibrahim Y, LaBree L, et al. Combined use of computed tomography coronary calcium scores and C-reactive protein levels in predicting cardiovascular events in nondiabetic individuals. Circulation 2002;106:2073-7.
Ridker PM. Clinical application of C-reactive protein for cardiovascular disease: detection and prevention. Circulation 2003; 107:363-369.
Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of Creactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular event. N Engl J Med2002; 347: 1557-1565. 16. Ridker PM, Hennekens CH, Buring JE, Rifai N. Creactive protein and other markers of inflammation in the predictor of cardiovascular disease in women. N Engl J Med.2000; 342:836-843.
Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon III RO, Criqui M, et al, Centers of Disease Control and Prevention,American Heart Association Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Center for Disease Control and Preventionand the American Heart Association. Circulation .2003;107:499-511.
Lagrand WK, Visser CA, Hermens WT, Niessen HW, Verheugt FW, Wolbink GJ, et al. C-reactive protein as a cardiovascular risk factor:more than an epiphenomenon? Circulation 1999;100:96-102.
Bhakdi S, Torzewski M, Klouche M, Hemmes M. Complement and atherogenesis: binding of CRP to degraded, nonoxidized LDL enhances complement activation. Arterioscler Thromb Vasc Biol 1999;19:2348-54. 20. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of Creactive protein onhuman endothelial cells. Circulation 2000; 102: 2165-8.
Mikkola TS, Clarkson TB. Estrogen replacement therapy, atherosclerosis, and vascular function. Cardiovasc Res 002; 53: 605-19.
Kelly C, Lyall H, Petrie JR, Gould GW, Connell JM, Sattar N . Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab.2001; 86:2453-55.
Fenkci V, Fenkci S, Yilmazer M, SerteserM. Decreased total antioxidant status and increased oxidative stress in women with polycystic ovary syndrome may contribute to the risk of cardiovascular disease. Fertil Steril 2003; 80: 123-7.
Kelly CC, Lyall H, Petrie JR, Gould GW, Connell JM, Sattar N. Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 2001;86:2453-5.
Tarkun I, Arslan BC, Canturk Z, Turemen E, Sahin T, Duman C. Endothelial dysfunction in young women with polycystic ovary syndrome:relationship with insulin resistance and low-grade chronic inflammation.J Clin Endocrinol Metab 2004;89:5592-6.
Diamanti-Kandarakis E, Alexandraki K, Piperi C, Protogerou A,Katsikis I, Paterakis T, et al. Inflammatory and endothelial markers inwomen with polycystic ovary syndrome. Eur J Clin Invest 2006;36:691-7.
Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus orkshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19- 25.
Information and ResourcesC-Reactive Protein (CRP).Acsees at http://www.webmd.com/a-to-zguides/ c-reactive-protein-crp?page=2.
Baillargeon JP, Jakubowicz DJ, Iuorno MJ, Jakubowicz S, Nestler JE. Effects of metformin and rosiglitazone, alone nd in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertil Steril 2004;82:893-902.
McAuley KA, Williams SM, Mann JI, Walker RJ, Lewis- arned NJ, Temple LA, Duncan AW. Diagnosing insulin resistance in the general population. Diabetes Care. 2001;24:460-4.
Baillargeon JP, Jakubowicz DJ, Iuorno MJ, Jakubowicz S,Nestler JE. Effects of metformin and rosiglitazone, alone and in combination, in non obese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertil Steril 2004;82:893-902.
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, TreacherDF, Turner RC .Homeostasis model assessment: insulinresistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-9.
World Health Organization. WHO study group revention of diabetes mellitus. Technical report series 844. World Health Organization,1994; Geneva.
Expert Committee on the Diagnosis and Classification Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003;26:3160-7.
Kaya C1, Akgül E, Pabuccu R. C-reactive protein and homocysteine levels are associated with abnormal heart rate recovery in women with polycystic ovary syndrome. Fertil Steril 2010;94:230-5.
Wu Y1, Zhang J, Wen Y, Wang H, Zhang M, Cianflone K. Increased acylation-stimulating protein, C-reactive protein, and lipid levels in young women with polycystic ovary syndrome. Fertil Steril 2009;91:213-9.
Guzelmeric K1, Alkan N, Pirimoglu M, Unal O, Turan C. Chronic inflammation and elevated homocysteine levels are associated with increased body mass index in women with polycystic ovary syndrome. Gynecol Endocrinol 2007;23:505-10.
Möhlig M, Spranger J, Osterhoff M, Ristow M, Pfeiffer AF, Schill T, et al. The polycystic ovary syndrome per se is not associated with increased chronic inflammation. Eur J Endocrinol 2004;150:525-32.
Huang CJ1, Zourdos MC, Jo E, Ormsbee MJ. Influence of physical activity and nutrition on obesity-related immune function. Scientific World Journal 2013 7;2013:752071.
Morin-Papunen L, Rautio K, Ruokonen A, Hedberg P, Puukka M, Tapanainen JS.Metformin reduces serum Creactive protein levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003; 88:4649-54.
Stadtmauer LA, Wong BC, Oehninger S 2002 Should patients with polycystic ovary syndrome be treated with metformin? Benefits of insulin sensitizing drugs in polycystic. Hum Reprod 2002;17:3016-26.
Galland L, “Diet and inflammation,” Nutrition in Clinical Practice 2010; 25: 634-40.
Haqq L, McFarlane J, Dieberg G, Smart N. The Effect of Lifestyle Intervention on Body Composition, Glycaemic Control and Cardio-Respiratory Fitness in Women With Polycystic Ovarian Syndrome: A Systematic Review and Meta-Analysis. Int J Sport Nutr Exerc Metab 2014; 25.
Chu MP1, Rong X, Wu RZ, Xiang RL, Xu Q, Zhang YH. Reducing plasma homocysteic acid lowers serum Creactive protein level in children with Kawasaki disease. Nan Fang Yi Ke Da Xue Xue Bao 2007; 27: 1762-3.
| Files | ||
| Issue | Vol 9, No 1 (March 2015) | |
| Section | Original Articles | |
| Keywords | ||
| CRP Female infertility Polycystic ovary syndrome (PCOS) | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
